Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.59)
# 201
Out of 5,154 analysts
144
Total ratings
49.21%
Success rate
42.18%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Downgrades: Neutral | $28 → $14 | $13.57 | +3.17% | 2 | Mar 4, 2026 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $105 → $150 | $70.70 | +112.16% | 4 | Feb 23, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $90 → $108 | $60.41 | +78.78% | 6 | Jan 21, 2026 | |
| IRD Opus Genetics | Initiates: Buy | $9 | $4.89 | +84.05% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $25.95 | +61.85% | 2 | Dec 1, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $30 → $40 | $24.08 | +66.11% | 2 | Nov 21, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $12 | $4.59 | +161.44% | 1 | Nov 19, 2025 | |
| NVAX Novavax | Reiterates: Buy | $18 → $16 | $9.98 | +60.32% | 20 | Nov 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $36.35 | +103.58% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $432.83 | +29.38% | 13 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $29.27 | +87.91% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.86 | +599.30% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $3.54 | +408.47% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.36 | +267.65% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $2.23 | +34.53% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.74 | +170.82% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $13.30 | +50.38% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.85 | +62.16% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $19.69 | +77.76% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $59.82 | -36.48% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $32.98 | +191.09% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.03 | +45.63% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $8.48 | +1,550.94% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.76 | +2,293.62% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $2.96 | +5,305.41% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $3.05 | +63.93% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.03 | +2,067.49% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $3.34 | +2,594.61% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.33 | +426.32% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $0.90 | +501,964.04% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.36 | +198,429.41% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $7.11 | +982.98% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.66 | +218,081.82% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $3.10 | +29.03% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $83.77 | -53.44% | 2 | Mar 18, 2020 |
Theravance Biopharma
Mar 4, 2026
Downgrades: Neutral
Price Target: $28 → $14
Current: $13.57
Upside: +3.17%
Nektar Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $105 → $150
Current: $70.70
Upside: +112.16%
Cytokinetics
Jan 21, 2026
Maintains: Buy
Price Target: $90 → $108
Current: $60.41
Upside: +78.78%
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $4.89
Upside: +84.05%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $25.95
Upside: +61.85%
Zymeworks
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $24.08
Upside: +66.11%
Nuvation Bio
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $4.59
Upside: +161.44%
Novavax
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $9.98
Upside: +60.32%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $36.35
Upside: +103.58%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $432.83
Upside: +29.38%
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $29.27
Upside: +87.91%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $2.86
Upside: +599.30%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $3.54
Upside: +408.47%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.36
Upside: +267.65%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $2.23
Upside: +34.53%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.74
Upside: +170.82%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $13.30
Upside: +50.38%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.85
Upside: +62.16%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $19.69
Upside: +77.76%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $59.82
Upside: -36.48%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $32.98
Upside: +191.09%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.03
Upside: +45.63%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $8.48
Upside: +1,550.94%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.76
Upside: +2,293.62%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $2.96
Upside: +5,305.41%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $3.05
Upside: +63.93%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.03
Upside: +2,067.49%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $3.34
Upside: +2,594.61%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.33
Upside: +426.32%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $0.90
Upside: +501,964.04%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.36
Upside: +198,429.41%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $7.11
Upside: +982.98%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.66
Upside: +218,081.82%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $3.10
Upside: +29.03%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $83.77
Upside: -53.44%